Adaptive Biotechnologies Corporation and Takeda entered into a translational collaboration, utilizing Adaptive’s clonoSEQ Assay to assess minimal residual disease, to facilitate the development and commercialization of Takeda’s pipeline of treatments for patients with lymphoid malignancies.
Caris Life Sciences and Flare Therapeutics formed a multi-year strategic collaboration to accelerate precision medicine approaches across five of Flare’s therapeutic programs into clinical trials through advanced molecular profiling approaches that guide patient selection and participation.
University of Florida Health researchers and Nuance Communications Inc., a Burlington, Massachusetts, firm that specializes in radiology voice recognition and AI deployment, formed a research alliance to develop artificial intelligence tools to make radiologists’ work more precise, safe, and efficient.
FDA approved Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.Â
FDA granted full approval to Keytruda for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.Â
The European Commission approved Libtayo (cemiplimab) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer with ≥1% PD-L1 expression. This includes patients that have no EGFR, ALK, or ROS1 aberrations and whose tumors are metastatic or locally advanced and not candidates for definitive chemoradiation.
Predictive Oncology has partnered with Integra Therapeutics to pursue a novel method to enhance Integra Therapeutics’ ability to use gene editing for future cancer therapies.
ArsenalBio’s lead product advances to clinical manufacturing following Thermo Fisher collaboration
Arsenal Biosciences Inc. advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T-cell therapy for platinum-resistant ovarian cancer. ArsenalBio’s work to develop multi-functional CAR-T cell therapies is enabled by Thermo Fisher’s Cell Therapy Systems portfolio of products, including the Gibco CTS Xenon Electroporation System and the Gibco CTS Rotea Counterflow Centrifugation System.
FDA issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design considerations to support accelerated approval applications. The accelerated approval pathway is commonly used for approval of oncology drugs in part due to the serious and life-threatening nature of cancer and because of available intermediate clinical endpoints likely to predict clinical benefit.
FDA granted accelerated approval to Zynyz (retifanlimab-dlwr) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.
